LncRNAs has been identified as regulators of Myeloid-derived suppressor cells in lung cancer.

Liu, Yifan; Han, Yukun; Zhang, Yanhua; Lv, Tongtong; Peng, Xiaochun; Huang, Jinbai

Liu, Yifan; Han, Yukun; Zhang, Yanhua; Lv, Tongtong; Peng, Xiaochun; Huang, Jinbai.

Afiliación

Liu Y; Department of Oncology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
Han Y; Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei, China.
Zhang Y; Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei, China.
Lv T; Department of Medical Imaging, School of Medicine, and Positron Emission Computed Tomography (PET) Center of the First Affiliated Hospital, Yangtze University, Jingzhou, Hubei, China.
Peng X; Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei, China.
Huang J; Laboratory of Oncology, Center for Molecular Medicine, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei, China.

Front Immunol ; 14: 1067520, 2023.

Article en En | MEDLINE | ID: mdl-36817434

Asunto(s)

Antineoplásicos; Carcinoma de Pulmón de Células no Pequeñas; Neoplasias Pulmonares; Células Supresoras de Origen Mieloide; ARN Largo no Codificante; Humanos; ARN Largo no Codificante/genética

Palabras clave

MDSC; immunotherapy; lncRNA; lung cancer; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / ARN Largo no Codificante / Células Supresoras de Origen Mieloide / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google